Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthélabo (Sanofi) is dated April 5, 2004. The report serves as a notification of a significant corporate action rather than a periodic financial statement. The primary subject is the proposed acquisition of Aventis.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on regulatory filings related to the merger.
Material Changes
The material event reported is the filing of a notification with the U.S. Federal Trade Commission (FTC) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 regarding Sanofi's offer for Aventis. Additionally, the company notes the issuance of an offer prospectus in Germany on March 11, 2004, applicable to holders of Aventis ordinary shares located in Germany.
Guidance, Outlook, and Risks
Management directs investors to review the registration statement on Form F-4 (File no. 333-112314) and the French prospectus (note d'information, visa number 04-0090) for detailed terms and conditions. The filing highlights that decisions regarding the tender of Aventis shares in Germany must be based exclusively on the German Offer prospectus. No specific financial guidance or risk factors regarding future performance are detailed in this specific text.
Investor Verification Checklist
- Verify the status of the FTC review of the Sanofi-Aventis merger.
- Review the Form F-4 registration statement (File no. 333-112314) for detailed transaction terms.
- Consult the French prospectus (visa 04-0090) available via the AMF website for French shareholders.
- Review the German offer prospectus for shareholders located in Germany.
- Confirm the exchange terms for Aventis ordinary shares for Sanofi ordinary shares.